ClinicalTrials.gov
ClinicalTrials.gov Menu

Study of ACE-083 in Patients With Facioscapulohumeral Muscular Dystrophy (FSHD)

The safety and scientific validity of this study is the responsibility of the study sponsor and investigators. Listing a study does not mean it has been evaluated by the U.S. Federal Government. Know the risks and potential benefits of clinical studies and talk to your health care provider before participating. Read our disclaimer for details.
ClinicalTrials.gov Identifier: NCT02927080
Recruitment Status : Recruiting
First Posted : October 6, 2016
Last Update Posted : May 14, 2018
Sponsor:
Information provided by (Responsible Party):
Acceleron Pharma, Inc.

Brief Summary:
Study A083-02 is a multicenter, Phase 2 study to evaluate the safety, tolerability, pharmacodynamics (PD), efficacy, and pharmacokinetics (PK) of ACE 083 in patients with FSHD to be conducted in two parts. Part 1 is open-label, dose-escalation and Part 2 is randomized, double-blind, and placebo-controlled.

Condition or disease Intervention/treatment Phase
Facioscapulohumeral Muscular Dystrophy Drug: ACE-083 Drug: ACE-083 or placebo Phase 2

Detailed Description:

Part 1 (dose escalation, open-label) Part 1 will consist of up to 6 cohorts (A to F) of patients and will evaluate multiple ascending dose levels of ACE-083 in either the tibialis anterior (TA) or biceps brachii (BB) muscle. Patients in each cohort will be enrolled in a 4-week screening period before beginning treatment. A Safety Review Team (SRT) will meet to review data for each cohort when at least 4 patients within a cohort have completed their Day 43 visit prior to dose escalation.

Part 2 (randomized, double-blind, placebo-controlled, with open-label extension) Prior to the initiation of Part 2, a review of safety and efficacy data from Part 1 will be conducted to determine whether cohorts for one or both muscles will be pursued in Part 2, as well as the recommended dose level for each muscle. A total of up to 56 new patients (28 patients per muscle) may be enrolled and randomized (1:1) to receive either ACE-083 (n=14/muscle) or placebo (n=14/muscle) bilaterally to either the TA or BB muscles (but not both). Patients will receive blinded study drug once every three weeks for approximately 6 months (9 doses).

Patients who complete the double-blind treatment period will immediately roll over to open-label treatment with ACE-083, receiving the same dose of active drug, bilaterally in either the TA or BB muscle, once every three weeks for approximately 6 months (8 doses). In Part 2, the SRT will periodically review blinded safety data for each muscle treated.

Study duration for Part 1 for each patient will be approximately 24 weeks, including a 4-week screening period, a 12-week treatment period, and an 8-week follow-up period after the last dose.

Study duration for Part 2 for each patient will be approximately 15 months, including a 1-month screening period, a 12-month treatment period (6-month double-blind, placebo-controlled and a 6-month open-label extension), and a 2-month follow-up period after the last dose


Study Type : Interventional  (Clinical Trial)
Estimated Enrollment : 92 participants
Allocation: Randomized
Intervention Model: Parallel Assignment
Masking: Quadruple (Participant, Care Provider, Investigator, Outcomes Assessor)
Primary Purpose: Treatment
Official Title: A Phase 2 Randomized, Double-Blind, Placebo-Controlled Study of ACE-083 in Patients With Facioscapulohumeral Muscular Dystrophy
Study Start Date : November 2016
Estimated Primary Completion Date : February 2020
Estimated Study Completion Date : May 2020


Arm Intervention/treatment
Experimental: ACE-083 (Part 1, Cohort 1)
ACE-083 150 mg IM, once every 3 weeks for up to 5 doses.
Drug: ACE-083
Recombinant fusion protein.
Experimental: ACE-083 (Part 1, Cohort 2)
ACE-083 200 mg IM, once every 3 weeks for up to 5 doses.
Drug: ACE-083
Recombinant fusion protein.
Experimental: ACE-083 (Part 1, Cohort 3)
ACE-083 up to 250 mg IM, once every 3 weeks for up to 5 doses.
Drug: ACE-083
Recombinant fusion protein.
Experimental: ACE-083 (Part 2, DB-PC, IM tibialis anterior muscle)
Double-Blind, Placebo-Controlled ACE-083 up to 250 mg IM (tibialis anterior muscle) or placebo, once every 3 weeks for up to 9 doses.
Drug: ACE-083 or placebo
Recombinant fusion protein or normal saline.
Experimental: ACE-083 (Part 2, PL, IM tibialis anterior muscle)
Open-Label ACE-083 up to 250 mg IM (tibialis anterior muscle) once every 3 weeks for up to 8 doses.
Drug: ACE-083
Recombinant fusion protein.
Experimental: ACE-083, (Part 2, DB-PC, IM biceps brachii muscle)
Double-Blind, Placebo-Controlled ACE-083 up to 250 mg IM (biceps brachii muscle) or placebo, once every 3 weeks for up to 9 doses.
Drug: ACE-083 or placebo
Recombinant fusion protein or normal saline.
Experimental: ACE-083 (Part 2, OP, biceps brachii muscle)
Open-Label ACE-083 up to 250 mg IM (biceps brachii muscle), once every 3 weeks for up to 8 doses.
Drug: ACE-083
Recombinant fusion protein.



Primary Outcome Measures :
  1. Safety and Tolerability (data collection on the incidence, nature and severity of adverse events). [ Time Frame: From initiation of treatment (Study Day 1) to end-of-study visit (Study Day 141). ]
    Adverse events will be recorded and coded in accordance with MedDRA v.20,0


Secondary Outcome Measures :
  1. Estimation of systemic exposure to ACE-083 following local intramuscular administration. [ Time Frame: From initiation of treatment (Study Day 1) to end-of-study visit (Study Day 141). ]
    Bioanlaytical assay for the quantitative of ACE-083 in serum

  2. Percent change from baseline in strength of injected muscle [ Time Frame: From initiation of treatment (Study Day 1) to end of treatment visit. ]
    Strength measurements by hand-held or fixed-system dynamometry (quantitative muscle testing).

  3. Percent change from baseline in function of injected muscle [ Time Frame: From initiation of treatment (Study Day 1) to end-of-study visit (Study Day 141). ]
    Function assessed by a battery of motor function tests; 4-stair climb, 6-minute walk test, gait analysis and performance of the upper limb (PUL) test

  4. Change from baseline in patient-reported outcome (PRO) measures [ Time Frame: From initiation of treatment (Study Day 1) to end-of-study visit (Study Day 141). ]
    PRO assessed by health-related quality of life and disease burden, as measured by the FSHD Health Index questionnaire (FSHD-HI).



Information from the National Library of Medicine

Choosing to participate in a study is an important personal decision. Talk with your doctor and family members or friends about deciding to join a study. To learn more about this study, you or your doctor may contact the study research staff using the contacts provided below. For general information, Learn About Clinical Studies.


Ages Eligible for Study:   18 Years and older   (Adult, Senior)
Sexes Eligible for Study:   All
Accepts Healthy Volunteers:   No
Criteria

Key Inclusion Criteria:

  1. Age ≥ 18 years
  2. Genetically-confirmed FSHD1 or FSHD2 (or a first-degree relative with genetically confirmed FSHD1 or FSHD2) and clinical findings meeting FSHD criteria
  3. Part 1 TA cohorts:

    1. 6-minute walk distance (6MWD) ≥ 150 meters (without a brace)
    2. Mild to moderate weakness in left and/or right ankle dorsiflexion

    Part 1 BB cohorts:

    a. Mild to moderate weakness in left and/or right elbow flexion

    Part 2 TA cohorts:

    1. 6MWD ≥ 150 and ≤ 500 meters (without a brace)
    2. Mild to moderate weakness in left and right ankle dorsiflexion

    Part 2 BB cohorts:

    a. Mild to moderate weakness in left and/or right elbow flexion

  4. Females of childbearing potential must have negative urine pregnancy test prior to enrollment and use highly effective birth control methods during study participation. Males must agree to use a condom during any sexual contact with females of childbearing potential while participating in the study even if he has undergone a successful vasectomy.

Key Exclusion Criteria:

  1. Histor y of active malignancy, with the exception of fully excised or treated basal cell carcinoma, cervical carcinoma in-situ, or ≤ 2 squamous cell carcinomas of the skin
  2. Symptomatic cardiopulmonary disease, significant functional impairment, or other co morbidities that in the opinion of the investigator would limit a patient's ability to complete strength and/or functional assessments on study
  3. Renal impairment (serum creatinine ≥ 2 times the upper limit of normal [ULN])
  4. Aspartate transaminase (AST) and/or alanine transaminase (ALT) ≥ 3 times ULN
  5. Increased risk of bleeding (i.e., due to hemophilia, platelet disorders, or use of any anticoagulation/platelet modifying therapies up to 2 weeks prior to Study Day 1; low dose aspirin [≤ 100 mg daily] is permitted)
  6. Major surgery within 4 weeks prior to Study Day 1
  7. Chronic systemic corticosteroids (≥ 2 weeks) within 4 weeks before Study Day 1 and for duration of study; intra-articular/topical/inhaled therapeutic or physiologic doses of corticosteroids are permitted
  8. Androgens or growth hormone within 6 months before Study Day 1 and for duration of study; topical physiologic androgen replacement is permitted
  9. Any condition that would prevent MRI scanning or compromise the ability to obtain a clear and interpretable scan of the TA or BB muscles, as applicable (e.g., pacemaker, knee/hip replacement, or metallic implants)

Information from the National Library of Medicine

To learn more about this study, you or your doctor may contact the study research staff using the contact information provided by the sponsor.

Please refer to this study by its ClinicalTrials.gov identifier (NCT number): NCT02927080


Contacts
Contact: Clinical Trial Manager clinicaltrials083@acceleronpharma.com

Locations
United States, California
University of California Los Angeles Medical Center Recruiting
Los Angeles, California, United States
Contact: Kianoush Kamali, CRC    310-825-3264    kkamali@mednet.ucla.edu   
Principal Investigator: Perry Shieh, MD         
University of California Davis Medical Center Recruiting
Sacramento, California, United States
Contact: Colleen Anthonisen, CRC       canthonisen@ucdavis.edu   
Principal Investigator: Nanette Joyce, MD         
United States, Iowa
University of Iowa Recruiting
Iowa City, Iowa, United States
Contact: Chandra Miller    319-384-9618    Chandra-Miller@uiowa.edu   
Principal Investigator: Katherine Mathews, MD         
United States, Kansas
University of Kansas Medical Center Recruiting
Kansas City, Kansas, United States
Contact: Ayla McCalley, CRC    913-945-9937    amccalley2@kumc.edu   
Principal Investigator: Jeffrey Statland, MD         
United States, Massachusetts
Brigham & Women's Hospital Recruiting
Boston, Massachusetts, United States
Contact: Kristen Roe       kroe@partners.org   
Principal Investigator: Anthony Amato, MD         
United States, Minnesota
University of Minnesota Recruiting
Minneapolis, Minnesota, United States
Contact: Paul & Sheila Wellstone Muscular Dystrophy Center    612-626-0822    mdcenter@umn.edu   
Principal Investigator: Georgios Manousakis, MD         
United States, Missouri
Washington University School of Medicine Recruiting
Saint Louis, Missouri, United States
Contact: Julaine Florence    314-362-6983      
Principal Investigator: Alan Pestronk, MD         
United States, New York
University of Rochester School of Medicine Recruiting
Rochester, New York, United States
Contact: Leann Lewis    585-275-7680      
Principal Investigator: Rabi Tawil, MD         
United States, North Carolina
Carolinas Healthcare System Neurosciences Institute Recruiting
Charlotte, North Carolina, United States
Contact: Lisa Ranzinger    704-446-0803      
Principal Investigator: Elena Bravver, MD         
Duke University Medical Center Recruiting
Durham, North Carolina, United States
Contact: Nikita Shah    919-613-5912    Nikita.shah@duke.edu   
Principal Investigator: Jeffrey Guptil, MD         
United States, Ohio
The Ohio State University Recruiting
Columbus, Ohio, United States
Contact: Julie Agriesti    614-293-4098    Julie.Agriesti@osumc.edu   
Principal Investigator: John Kissel, MD         
United States, Oregon
Oregon Health & Science University Recruiting
Portland, Oregon, United States
Contact: Diana Dimitrova, CRC    503-494-7269    dimitrov@ohsu.edu   
Principal Investigator: Chafic Karam, MD         
United States, Pennsylvania
University of Pennsylvania Recruiting
Philadelphia, Pennsylvania, United States
Contact: Lauren Elman, MD       Lauren.Elman@uphs.upenn.edu   
Principal Investigator: Lauren Elman, MD         
United States, Utah
University of Utah Recruiting
Salt Lake City, Utah, United States
Contact: Bryant Gordon, CRC    801-585-5052    bryant.gordon@genetics.utah.edu   
Principal Investigator: Nicholas Johnson, MD         
Canada, Alberta
University of Calgary Recruiting
Calgary, Alberta, Canada
Contact: Jose Martinez    403-210-7009    jamarti@ucalgary.ca   
Principal Investigator: Lawrence Korngut, MD         
Canada, Ontario
London Health Sciences Centre Recruiting
London, Ontario, Canada
Contact: Rhiannon Hicks    519-685-8441    Rhiannon.hicks@lhsc.on.ca   
Principal Investigator: Craig Campbell, MD         
Canada, Quebec
Montreal Neurological Institute & Hospital Recruiting
Montréal, Quebec, Canada
Contact: Xin Di Dong    514-398-5744    xin.dong@mcgill.ca   
Principal Investigator: Erin O'Ferrall, MD         
Sponsors and Collaborators
Acceleron Pharma, Inc.

Responsible Party: Acceleron Pharma, Inc.
ClinicalTrials.gov Identifier: NCT02927080     History of Changes
Other Study ID Numbers: A083-02
ACE-083 ( Other Identifier: Acceleron Pharma Inc. )
First Posted: October 6, 2016    Key Record Dates
Last Update Posted: May 14, 2018
Last Verified: May 2018

Keywords provided by Acceleron Pharma, Inc.:
FSHD

Additional relevant MeSH terms:
Muscular Dystrophies
Muscular Dystrophy, Facioscapulohumeral
Muscular Disorders, Atrophic
Muscular Diseases
Musculoskeletal Diseases
Neuromuscular Diseases
Nervous System Diseases
Genetic Diseases, Inborn